Similar articles

• [Concerning: F. Cavalli: Adriamycin/cyclophosphamide: current standard in adjuvant therapy of breast carcinoma? (Schweiz Med. Wochenschr 1994; 124:1882-1884)].

  Sauter C. Sauter C. Schweiz Med Wochenschr. 1995 Jan 10;125(1-2):47. Schweiz Med Wochenschr. 1995. PMID: 7839111 German. No abstract available.
• [Adriamycin/cyclophosphamide: current standard in adjuvant therapy for breast carcinoma?].

  Sauter C. Sauter C. Schweiz Med Wochenschr. 1994 Oct 29;124(43):1879-81. Schweiz Med Wochenschr. 1994. PMID: 7973513 German. No abstract available.
• [Adriamycin/cyclophosphamide: current standard in the adjuvant therapy of breast carcinoma? Or: how should one really put this question?].

  Cavalli F. Cavalli F. Schweiz Med Wochenschr. 1994 Oct 29;124(43):1882-4. Schweiz Med Wochenschr. 1994. PMID: 7973514 Clinical Trial. German. No abstract available.
• Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.

  Hudis CA, Seidman AD, Baselga J, Raptis G, Lebwohl D, Gilewski T, Currie V, Moynahan ME, Sklarin N, Fennelly D, et al. Hudis CA, et al. Semin Oncol. 1995 Dec;22(6 Suppl 15):18-23. Semin Oncol. 1995. PMID: 8643965
• Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma.

  Fornier MN, Seidman AD, Theodoulou M, Moynahan ME, Currie V, Moasser M, Sklarin N, Gilewski T, D'Andrea G, Salvaggio R, Panageas KS, Norton L, Hudis C. Fornier MN, et al. Clin Cancer Res. 2001 Dec;7(12):3934-41. Clin Cancer Res. 2001. PMID: 11751485 Clinical Trial.